Rugonersen

N/A

Report date: 2025/04/25 11:16:01
NME

Base Information

Drug NameRugonersen
Drug Alias NameRO-7248824RG-6091UBE3A-LNA
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ag
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdOak Hill Bio Inc
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A